Understanding peptide half-life

The half-life you read on a label

Half-life (t½) is the time it takes for the plasma concentration of a compound to fall to half of its starting value. On a label or in a pharmacology paper, this is usually the elimination half-life — the terminal phase after distribution equilibrium is reached. It is one of the most useful single numbers in pharmacokinetics because it lets you predict several practical things at once: how long a single dose keeps producing measurable effects, how often the compound needs to be dosed to maintain a steady blood level, and how long it takes to reach steady state (roughly 4–5 half-lives). But half-life is not the whole pharmacokinetic story, and treating it as if it were causes common misconceptions about how peptides actually work.

Why native peptides have such short half-lives

Most native peptide hormones have plasma half-lives measured in minutes rather than hours or days. Native GLP-1 has a t½ of about 2 minutes because it is degraded rapidly by dipeptidyl peptidase-4 (DPP-4). Native GHRH is also inactivated by DPP-4 within minutes. Native α-MSH is degraded by peptidases and cleared quickly. This short native half-life is a feature of physiological signalling: pulsatile hormone release with rapid clearance produces the peak-to-trough oscillations that downstream tissues respond to. Continuous exposure to hormones at high levels is generally pathological (Cushing's syndrome from continuous cortisol; acromegaly from continuous GH). But for pharmaceutical use, minutes-long half-life is impractical — the compound would need to be delivered by continuous infusion. The entire history of peptide drug development is largely a history of engineering longer half-lives while preserving receptor pharmacology.

The engineering strategies

Several distinct strategies extend peptide half-life. Amino-acid substitution at the DPP-4 cleavage site: replacing residues near the N-terminus that DPP-4 recognises makes the compound resistant to degradation. Semaglutide's Aib-2 substitution and CJC-1295's stabilising modifications work this way. Fatty-acid conjugation: attaching a long-chain fatty acid (semaglutide uses a C18 diacid) drives non-covalent binding to serum albumin, which sequesters the peptide from proteolysis and slows renal clearance. This extends half-life from minutes to about a week (semaglutide t½ ≈ 165 hours). Drug affinity complex (DAC) approaches: chemical modifications that covalently link the peptide to albumin. CJC-1295 DAC uses this — its half-life is about a week vs the No DAC variant's hours. Depot formulation: encapsulating the peptide in a slow-release carrier (Scenesse's implant matrix). Each strategy has different pharmacokinetic implications, and knowing which is used explains why a compound behaves the way it does.

Pulsatile vs continuous — when short half-life is a feature

For some pharmacological effects, short half-life is not a limitation to engineer around — it is a feature required by the underlying biology. Growth hormone releasing hormone is the classical example: the pituitary somatotrophs respond to pulsatile GHRH signal rather than continuous elevation. Continuous GHRH signal produces receptor desensitisation and reduced GH release; pulsatile signal maintains responsiveness and drives normal downstream IGF-1 elevation. This is why CJC-1295 No DAC (short half-life, pulsatile pharmacology) is often preferred over CJC-1295 DAC (extended half-life, continuous elevation) for GH secretagogue applications. It is also why native GHRH physiology involves brief neuronal firing bursts rather than sustained secretion. Understanding whether a receptor system prefers pulsatile or continuous activation is essential to reading pharmacokinetic engineering choices correctly — not every peptide is improved by a longer half-life.

What half-life does not tell you

Half-life is a plasma-concentration measure, but plasma concentration is not always what determines effect duration. Two important cases: first, some peptides are taken up by target tissues and continue producing effects after plasma levels have fallen — SS-31 concentrates 1000-fold in inner mitochondrial membrane and its effect duration is governed by mitochondrial pool clearance rather than plasma half-life. Second, some peptides work by triggering downstream cascades that continue after the peptide is cleared — kisspeptin's pulse triggers a downstream GnRH-LH-oestradiol cascade that plays out over hours despite kisspeptin itself clearing in minutes. Half-life is a good default first-order predictor of dosing interval, but it does not capture all the pharmacology. Reading the mechanism of action alongside the pharmacokinetics is what gives an accurate picture of how a compound will behave.

Common questions

References

• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide· Lau J, Bloch P, Schäffer L, et al. · 2015
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone· Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · 2006
• TAZPOWER — a phase 2/3 randomised placebo-controlled crossover study of elamipretide in Barth syndrome and its open-label extension· Reid Thompson W, Manuel R, Abbruzzese C, et al. · 2021

Links open external, peer-reviewed sources. Healthy Mango does not host trial data.